🇺🇸 intravenous lipid in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 7

Most-reported reactions

1. Shock — 3 reports (42.86%)
2. Acute Lung Injury — 1 report (14.29%)
3. Cardiotoxicity — 1 report (14.29%)
4. Hyperlipidaemia — 1 report (14.29%)
5. Hypoglycaemia — 1 report (14.29%)

Source database →

Frequently asked questions

Is intravenous lipid approved in United States?

intravenous lipid does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for intravenous lipid in United States?

University of Rochester is the originator. The local marketing authorisation holder may differ — check the official source linked above.